About Sputnik Light

Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V – the world’s first registered vaccine against coronavirus.

The Sputnik Light vaccine, like Sputnik V, is based on a proven well-studied human adenovirus vector platform; these vectors cause the common cold and have peacefully coexisted with humanity for millenia.

Safety of Sputnik Light, as the first component of Sputnik V, was confirmed by real-world data from UAE, Bahrain, Argentina, Russia, Mexico, Serbia, San Marino, Philippines, Libya, Paraguay, Hungary, Azerbaijan and Belarus.

Sputnik Light, the first component of Sputnik V, is a safe and approved stand-alone one-shot vaccine

proven efficacy against infection,
higher than that of most two-shot vaccines

The efficacy against hospitalization and severe disease is even higher

Sputnik Light is also a leading booster shot

for people previously infected with COVID-19
for revaccinations after Sputnik V or other vaccines

Sputnik Light as a stand-alone vaccine is highly effective against Delta and other mutations

efficacy against
infection by Delta

efficacy in the age
group below 60

higher than that of most two-shot vaccines

Efficacy against hospitalization and severe disease is even higher

Sputnik Light efficacy as a booster will be close to that of two shots of Sputnik V against Delta

effective against
infection

effective against
hospitalization

Sputnik Light as a booster increases virus neutralizing activity against Omicron variant considerably

developed neutralizing antibodies
against Omicron variant

Sputnik Light has a long-lasting protection, which even increases over 4-6 months following the vaccination.

Many other vaccines showed dramatic decrease in efficacy against Delta variant to below 50% within the same time period.

Sputnik Light safety was confirmed by real-world data from multiple countries and by over 20 publications in the leading international scientific journals.

Sputnik Light is safe and effective in combination with other vaccines as confirmed by joint international clinical trials with the AstraZeneca, Sinopharm and Moderna vaccines
This vaccine coctail or mix & match approach has been poineered by Sputnik V.

Sputnik Light, the first component of Sputnik V, became a significant part of immunization programme in Argentina

40,000
35,000
30,000
25,000
20,000
15,000
10,000
5,000

Over 35 times reduction in new COVID-19 cases over the last 4 months

daily new cases
daily new cases (7 days average)

Jun, 2021

Jul, 2021

Aug, 2021

Sep, 2021

Oct, 2021

Source: JHU CSSE COVID-19 Data

Phase I/II of the Safety and Immunogenicity Study of the Sputnik Light vaccine has demonstrated that:

Sputnik Light can elicit the development of antigen specific IgG antibodies in 96.9% of individuals on the 28th day after vaccination;
The Sputnik Light vaccine elicits the development of virus neutralizing antibodies in 91.67% of individuals on the 28th day post immunization;
Cellular immune response against the S Protein of SARS-CoV-2 develops in 100% of volunteers on the 10th day;
The immunization of individuals with pre-existing immunity against SARS-CoV-2 with Sputnik Light can elicit the increase of the level of antigen specific IgG antibodies by more than 40x in 100% of subjects 10 days after immunization;
No serious adverse events were registered after vaccination with Sputnik Light.

Ministry of Health Registration Certificate